ProPhase Labs, Inc. (PRPH)

$10.6706

+0.00 (+0.01%)
Rating:
Recommendation:
Neutral
Symbol PRPH
Price $10.6706
Beta -0.270
Volume Avg. 0.17M
Market Cap 167.369M
Shares () -
52 Week Range 4.76-15.25
1y Target Est -
DCF Unlevered PRPH DCF ->
DCF Levered PRPH LDCF ->
ROE 32.04% Strong Buy
ROA 17.77% Buy
Operating Margin -
Debt / Equity 50.00% Neutral
P/E 9.97 Strong Buy
P/B 2.49 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PRPH news


Mr. Ted Karkus
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Capital Market

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; SARS-CoV-2 (COVID-19) and COVID-19 viral mutation polymerase chain reaction tests through saliva and nasal swab methods; and other respiratory pathogen panel molecular testing services, as well as personal genomics products and services. It serves national chain drug, internet-based, and various regional retailers. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.